Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein.

Abstract

The importance of the dipeptidyl peptidase 4 (DPP4) gene family in regulating critical biochemical pathways continues to emerge. The two most well-studied members of the family, DPP4 and fibroblast activation protein (FAP), have been investigated both as therapeutic targets for disease and as diagnostic biomarkers. The interest in DPP4 and FAP as potential disease biomarkers has been driven primarily by observations of altered expression profiles in inflammatory diseases and cancer. Furthermore, the stability and persistence of soluble DPP4 and FAP in the serum make them attractive candidate serology markers. This review summarises investigations into DPP4 and FAP as biomarkers of autoimmune disease, gut inflammation, psychosomatic disorders and malignancy and discusses their potential likelihood as clinically useful tools.

• Authors: Roger Yazbeck, Simone E Jaenisch, Catherine A Abbott
• Journal: Protoplasma (Protoplasma) Vol. 255 Issue 1 Pg. 375-386 (Jan 2018) ISSN: 1615-6102 [Electronic] Austria
• PMID: 28620698 (Publication Type: Journal Article, Review)

Chemical References

• Biomarkers
• Membrane Proteins
• Endopeptidases
• Dipeptidyl Peptidase 4
• Serine Endopeptidases
• fibroblast activation protein alpha
• Gelatinases

Topics

• Biomarkers (metabolism)
• Dipeptidyl Peptidase 4 (metabolism)
• Endopeptidases
• Gelatinases (metabolism)
• Humans
• Inflammation (genetics, metabolism)
• Membrane Proteins (genetics, metabolism)
• Serine Endopeptidases (metabolism)